NASDAQ:NUWE Nuwellis (NUWE) Stock Price, News & Analysis $2.05 -0.15 (-6.82%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.86 -0.19 (-9.02%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Nuwellis Stock (NASDAQ:NUWE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nuwellis alerts:Sign Up Key Stats Today's Range$1.95▼$2.3550-Day Range$2.05▼$36.7552-Week Range$1.95▼$447.72Volume142,752 shsAverage Volume194,357 shsMarket Capitalization$157.85 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays. The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting. This technology is used in hospitals, specialty renal centers and other acute care facilities. The system’s design emphasizes ease of use for clinicians, with automated control features and real‐time monitoring that support individualized treatment plans and help mitigate the risks associated with rapid fluid shifts. Originally founded as Renal Solutions in 2005, the company adopted the Nuwellis name in 2016 to reflect a broader commitment to advancing fluid management therapies. Headquartered in Plymouth, Minnesota, Nuwellis holds both FDA clearance in the United States and CE Mark approval for distribution across Europe. Its sales and distribution network serves acute care hospitals and renal clinics across North America and select international markets. Nuwellis continues to invest in research and development aimed at expanding the clinical applications of its ultrafiltration technology. The company’s leadership team includes seasoned executives with extensive experience in medical devices and healthcare innovation. Ongoing efforts focus on regulatory approvals, commercial partnerships and clinical studies to validate new indications and broaden access to its therapies worldwide.AI Generated. May Contain Errors. Read More Nuwellis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreNUWE MarketRank™: Nuwellis scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingNuwellis has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageNuwellis has only been the subject of 1 research reports in the past 90 days.Read more about Nuwellis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuwellis is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuwellis is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuwellis has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nuwellis' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted150.23% of the float of Nuwellis has been sold short.Short Interest Ratio / Days to CoverNuwellis has a short interest ratio ("days to cover") of 0.64, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nuwellis has recently increased by 50.19%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuwellis does not currently pay a dividend.Dividend GrowthNuwellis does not have a long track record of dividend growth. News and Social Media2.5 / 5News SentimentN/A News SentimentNuwellis has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nuwellis this week, compared to 2 articles on an average week.Search Interest1 people have searched for NUWE on MarketBeat in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nuwellis insiders have not sold or bought any company stock.Percentage Held by Insiders1.60% of the stock of Nuwellis is held by insiders.Percentage Held by Institutions3.13% of the stock of Nuwellis is held by institutions.Read more about Nuwellis' insider trading history. Receive NUWE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NUWE Stock News HeadlinesNuwellis (NASDAQ:NUWE) Upgraded at Wall Street ZenJuly 18, 2026 | americanbankingnews.comNuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal TherapiesJuly 16, 2026 | globenewswire.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.July 25 at 1:00 AM | Chaikin Analytics (Ad)Nuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026July 7, 2026 | globenewswire.comNuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)June 26, 2026 | globenewswire.comNuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® InstallationsJune 25, 2026 | globenewswire.comIncoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to ShareholdersJune 24, 2026 | globenewswire.comNuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education SummitJune 18, 2026 | globenewswire.comSee More Headlines NUWE Stock Analysis - Frequently Asked Questions How have NUWE shares performed this year? Nuwellis' stock was trading at $60.90 at the beginning of the year. Since then, NUWE stock has decreased by 96.6% and is now trading at $2.05. How were Nuwellis' earnings last quarter? Nuwellis, Inc. (NASDAQ:NUWE) posted its quarterly earnings data on Tuesday, May, 12th. The company reported ($73.15) EPS for the quarter, missing the consensus estimate of ($35.00) by $38.15. The firm earned $2.40 million during the quarter, compared to analyst estimates of $2.09 million. Nuwellis had a negative trailing twelve-month return on equity of 32,351.83% and a negative net margin of 214.90%. Read the conference call transcript. When did Nuwellis' stock split? Shares of Nuwellis reverse split on the morning of Friday, June 28th 2024.The 1-35 reverse split was announced on Friday, June 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Nuwellis? Shares of NUWE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuwellis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuwellis investors own include Verb Technology (VERB), TransCode Therapeutics (RNAZ), Exela Technologies (XELA), AMC Entertainment (AMC), BIOLASE (BIOL) and Company Calendar Last Earnings5/12/2026Today7/25/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 NUWE's financial health is in the Red zone, according to TradeSmith. NUWE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:NUWE CIK1506492 Webwww.nuwellis.com Phone(952) 345-4200FaxN/AEmployees70Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2,238.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.52 million Net Margins-214.90% Pretax Margin-217.17% Return on Equity-32,351.83% Return on Assets-249.08% Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick Ratio1.09 Sales & Book Value Annual Sales$8.77 million Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book Value$55.31 per share Price / Book0.04Miscellaneous Outstanding Shares77,000Free Float76,000Market Cap$157.85 thousand OptionableNot Optionable Beta0.29 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:NUWE) was last updated on 7/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuwellis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuwellis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
